LEAP: Intravenous VAL-1221 Lafora Expanded Access Protocol
Study Details
Study Description
Brief Summary
Only qualified physicians treating a Lafora Disease patient may request VAL-1221 Expanded Access treatment under the Parasail Lafora Expanded Access Protocol (LEAP). According to FDA guidance, this protocol can enroll up to 10 patients. However, individual patient inclusion will ultimately be dependent on protocol eligibility, site geography, treatment requirements, and available supply of the investigational therapy. Inquiring physicians can submit a request by contacting the Central Contact personnel listed below in Contacts/Locations.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Documented genetic diagnosis of Lafora Disease (LD) based on likely pathogenic or pathogenic variants in both alleles of either the EPM2A or the EPM2B gene
-
Mid-stage in evolution of LD between 12 and 28 years of age
-
Able and willing to comply with the protocol, including travel to Protocol Center, procedures, measurements and visits, including:
-
Adequately supportive psychosocial circumstances, in the opinion of the Investigator
-
Caregiver/trial partner committed to facilitate patient's involvement in the study who is reliable, competent, at least 18 years of age
Exclusion Criteria:
- Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the participant unsafe for inclusion or could interfere with the participant participating in or completing the protocol
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Parasail, LLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VAL1221-LEAP-01